Epicrispr Reports Positive Six-Month Data at The World Muscle Society Meeting Demonstrating Increased Lean Muscle Volume and Muscle Strength in FSHD Patients Treated with EPI-321

Lean Muscle Volume Increased Across Total, Upperand Lower-Body Composite Measures at Month 6 Strength Gains on Quantitative Muscle Testing Track with Muscle Volume Increases, Including in Upper-Body Muscle Groups Commonly Affected Early in FSHD SAN FRANCISCO–(BUSINESS WIRE)– Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced updated six-month clinical data from the ongoing open-label, … Read more